Patrick Hwu: What is the “obesity paradox” in cancer immunotherapy?
Patrick Hwu, President and CEO at Moffitt Cancer Center, shared a recent article by Mark Yarchoan et al. on LinkedIn:
“What is the ‘obesity paradox’ in cancer immunotherapy?
Although obesity increases the risk of cancer, it’s also been linked with better outcomes for some patients treated with immune checkpoint inhibitors (ICIs), a type of immunotherapy.
In this study, Mark Yarchoan et al. evaluated a diverse cohort of patients across multiple cancer types. They found obese patients responded better to ICIs than those with lower body mass index (BMI). Obesity was associated with lower levels of inhibitory cytokines and greater expression of t-cell exhaustion markers.
We’ve been trying to unravel this obesity paradox for many years, and this interesting analysis helps us better understand the mechanism and how we can tailor immunotherapy to improve outcomes.”
“Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade”
Authors: Stephanie L Alden, Soren Charmsaz, Howard L Li, Hua-Ling Tsai, Ludmila Danilova, Kabeer Munjal, Madelena Brancati, Aanika Warner, Kathryn Howe, Ervin Griffin, Mari Nakazawa, Chris Thoburn, Jennifer Gizzi, Alexei Hernandez, Nicole E Gross, Erin M Coyne, Elsa Hallab, Sarah S Shin, Jennifer Durham, Evan J Lipson, Yasser Ged, Marina Baretti, Jean Hoffman-Censits, Tanguy Y Seiwert, Aditi Guha, Sanjay Bansal, Laura Tang, G Scott Chandler, Rajat Mohindra, Rachel Garonce-Hediger, Elizabeth M Jaffee, Won Jin Ho, Chester Kao and Mark Yarchoan
More posts featuring Patrick Hwu.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023